Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with
Proactive and he also maps out the next steps for the company as they move closer to Phase III and potential partnerships
viewAntibe Therapeutics Inc
Antibe Therapeutics releases data from company’s Phase II placebo-controlled efficacy study
Quick facts: Antibe Therapeutics Inc
Price: 0.35 CAD
TSX-V:ATE
Market: TSX-V
Market Cap: $134.91 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Industry & services
US stocks close higher as coronavirus stimulus talks advance
4 days, 4 hours ago
Tech
Intel sees third quarter margins tumble as consumers buy cheaper PCs and...
1 day, 13 hours ago
Health
CytoDyn provide update on their path to approval for treatment of COVID-19
1 day, 5 hours ago
